Compare Abeona Therapeutics Inc (ABEO) vs Consolidated Edison, Inc. (ED) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Consolidated Edison, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Consolidated Edison, Inc. trades at $112 (market cap $41.64B). The key difference: Consolidated Edison, Inc. is far larger — about 111.5× Abeona Therapeutics Inc's market cap, and Consolidated Edison, Inc. pays a 3.08% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | ED | |
|---|---|---|
Market Cap | $373.32M | $41.64B |
Sector | Health | Utilities |
52-Week High | $7.23 | $115.46 |
52-Week Low | $4.17 | $95.37 |
Enterprise Value | $228.22M | $68.67B |
Dividend Yield | — | 3.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Consolidated Edison (ED) trades at $112.99, down 0.88% on the day, with a bullish technical signal from moving averages. The utility company reported mixed Q1 2026 earnings but maintains steady revenue growth and a 12.52% net income margin. Recent news highlights grid upgrades and a new $2 billion equity offering program announced May 8, 2026.
ED offers stable dividend income with a 52-year growth streak but faces analyst caution with 63% hold ratings. Upside potential exists from infrastructure investments, while risks include debt levels and regulatory pressures. The consensus price target of $103.50 suggests limited near-term appreciation from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →
